Developing natural products to improve cognitive function in early Alzheimer's disease
A Drug Discovery Platform to Prioritize Development of Natural Product Neuromodulators for Treating Cognitive Impairment
This study is exploring natural products from plants that might help improve brain function for people with Mild Cognitive Impairment (MCI), which can lead to Alzheimer's Disease, by combining these treatments with healthy habits like exercise and better eating.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sensorium Therapeutics INC NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11237693 on NIH RePORTER |
What this research studies
This research focuses on identifying and developing natural products that can enhance neuroplasticity to treat Mild Cognitive Impairment (MCI), a precursor to Alzheimer's Disease (AD). By leveraging compounds derived from medicinal plants, the project aims to create safe and effective treatments that can be administered before the onset of more severe symptoms. The approach includes both pharmacological interventions and holistic methods, such as exercise and dietary changes, to improve cognitive function and memory. The research seeks to address the critical window for intervention in patients showing early signs of cognitive decline.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing Mild Cognitive Impairment or those identified as being at risk for Alzheimer's Disease.
Not a fit: Patients with advanced Alzheimer's Disease or other forms of dementia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve cognitive function and quality of life for individuals at risk of developing Alzheimer's Disease.
How similar studies have performed: Previous research has shown promise in using natural products and neuroplasticity modifiers for cognitive enhancement, indicating potential success for this approach.
Where this research is happening
Boston, United States
- Sensorium Therapeutics INC — Boston, United States (Active)
Researchers
- Principal investigator: Brown, Jeffrey M. — Sensorium Therapeutics INC
- Study coordinator: Brown, Jeffrey M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.